2023年乳腺标志物细胞学实践:美国病理学家学会调查结果
美国病理学家学会(CAP)2023年向参与非妇科细胞病理教育计划的实验室发放乳腺标志物细胞学实践补充问卷,分析国内与国际实验室实践。
要点
- ER/PR(98.9%)与HER2(93.2%)检测最普遍,PD-L1与错配修复约两成。
- 全部应答者(165/165)验证细胞块,仅12.9%使用数字成像平台。
核心结论
- 这是CAP首次调查乳腺标志物细胞学实践,结果揭示不同机构类型及国内与国际实验室之间存在差异,为后续研究与指南制定提供基线。
研究设计与样本
- 基于CAP乳腺标志物细胞学实践补充问卷,发放给参与2023年CAP非妇科细胞病理教育计划的实验室,分析应答实验室数据。
主要发现
- 细胞学标本检测标志物包括ER/PR(98.9%;175/177)、HER2(93.2%;165/177)、Ki-67(48.6%;86/177)、PD-L1(20.9%;37/177)、错配修复(19.8%;35/177)。
- 细针穿刺是最常验证的标本类型(85.3%;133/156),其次为体液(82.1%;128/156)。
- CytoLyt为最常用收集介质(55.4%;87/157),formalin为最常用固定剂(90.4%;151/167)。
- 44家实验室(28.0%;44/157)要求细胞量充足性以判读细胞学标本乳腺标志物。
关键数值与推荐
- 全部应答者验证细胞块(100.0%;165/165),少数验证细胞离心涂片(3.0%;5/165)、液基玻片(3.0%;5/165)、风干直接涂片(2.4%;4/165)等。
- 收集介质依次为平衡盐溶液(16.6%;26/157)、RPMI Medium(13.4%;21/157)、CytoRich Red(9.6%;15/157)。
- 固定剂中乙醇占5.4%(9/167)、甲醇占3.0%(5/167)。
- 数字成像平台使用率为12.9%(22/171)。
临床怎么用
- 乳腺标志物细胞学检测以细胞块、细针穿刺标本和福尔马林固定为主流实践,可作为实验室开展或比对相关检测的参考基线。
局限性
- 为问卷调查数据,仅反映自愿参与CAP教育计划实验室的实践,原文未报告应答率及未应答实验室特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The College of American Pathologists (CAP) surveys provide national benchmarks of pathology practice. OBJECTIVE.—: To investigate breast biomarker cytology practice in domestic and international laboratories in 2023. DESIGN.—: We analyzed data from the CAP Breast Biomarker Cytology Practice Supplemental Questionnaire that was distributed to laboratories participating in the 2023 CAP Nongynecologic Cytopathology Education Program. RESULTS.—: Twenty-five percent (180 of 728) of responding laboratories routinely evaluated breast biomarkers in cytology specimens. Breast biomarkers evaluated in cytology specimens included estrogen receptor/progesterone receptor (98.9%; 175 of 177), human epidermal growth factor receptor 2 (HER2) (93.2%; 165 of 177), Ki-67 (48.6%; 86 of 177), programmed death ligand-1 (PD-L1) (20.9%; 37 of 177), and mismatch repair (19.8%; 35 of 177). Fine-needle aspiration was the most validated specimen type (85.3%; 133 of 156), followed by body fluids (82.1%; 128 of 156). All respondents validated cell blocks (100.0%; 165 of 165), with a few laboratories also validating cytospin slides (3.0%; 5 of 165), liquid-based slides (3.0%; 5 of 165), air-dried direct smears (2.4%; 4 of 165), and others. CytoLyt was the most used collection medium (55.4%; 87 of 157), followed by balanced salt solution (16.6%; 26 of 157), Roswell Park Memorial Institute Medium (13.4%; 21 of 157), and CytoRich Red (9.6%; 15 of 157). Almost all laboratories indicated routinely using formalin (90.4%; 151 of 167) as fixative, while a few laboratories used other types of fixative (ethanol [5.4%; 9 of 167], methanol [3.0%; 5 of 167]). Digital imaging platforms were used by only 12.9% (22 of 171) of responding laboratories. Forty-four laboratories (28.0%; 44 of 157) required cellularity adequacy for interpreting breast biomarkers on cytologic specimens. Additionally, some significant differences in breast biomarker testing practice were identified among different institution types and between domestic and international laboratories. CONCLUSIONS.—: This is the first survey from the CAP to investigate breast biomarker cytology practices. The findings reveal some differences among institution types and between domestic and international laboratories. These data provide a baseline for and support further studies and/or guidelines to promote and refine these practices.
引用
- Li Z, King A, Souers RJ, et al. Breast Biomarker Cytology Practice in 2023: Results of a College of American Pathologists Survey. Arch Pathol Lab Med. 2025. PMID: 40331833. doi:10.5858/arpa.2025-0023-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。